GLPwatch
Gliptins, exenatide, liraglutide: "intestinal obstruction".
Prescrire Int · 2016
Last updated 2026-05-28| Journal | Prescrire Int, 2016 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.05 |
| NIH percentile | 5 |
| Molecules | liraglutide, exenatide |
Abstract
Reduced gastrointestinal motility exposes to potentially serious consequences.
Verbatim abstract via PubMed 26942257 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.